KR20120058029A - Pharmaceutical composition for nasal administration comprising mometasone furoate and azelastine hydrochloride - Google Patents

Abstract

PURPOSE: A pharmaceutical composition containing mometasone furoate, azelastine hydrochloride, and thaumatin is provided to enhance drug compliance. CONSTITUTION: A pharmaceutical composition for endonasal adminisration contains 0.01-1.0 w/v% of mometasone furoate and 0.05-1.0 w/v% of azelastine hydrochloride. The pharmaceutical composition also contains 0.1-0.5 w/v% of thaumatin as an agent for relieving bitter taste and stimulation. The pharmaceutical composition further contains 1.0-5.0 w/v% of tackifier, 0.2-0.6 w/v% of buffer, 0.001-0.1 w/v% of surfactant, 5.0-10.0 w/v% of isotonic agent, 0.01-1.0 w/v% of stabilizing agent, and 0.002-0.05 w/v% of preservative in an aqueous medium. The pharmaceutical composition for endonasal administration is formulated in a nasal spray.

Description

Pharmaceutical composition for nasal administration comprising mometasone furoate and azelastine hydrochloride}

The present invention relates to a pharmaceutical composition for intranasal administration comprising mometasone furoate and azelastine hydrochloride, and more particularly, to reduce nausea and irritation of azelastine hydrochloride using tomatin to improve nausea. To a pharmaceutical composition.

Mometasone furoate is a steroidal drug used to treat allergic rhinitis, and it is known to be excellent in sustaining symptomatic effects. Therefore, when these two drugs are administered as a combination, it is expected to have an excellent effect on the treatment of long-term allergic rhinitis with immediate symptom improvement.

WO97 / 01337 discloses azelastine or salts thereof; Nasal spray or nasal drop formulations have been disclosed including beclomethasone, flunisolid, triamcinolone, dexamethasone and budesonide. In addition, WO 2003/105856 discloses azelastine or salts thereof; Pharmaceutical formulations (eg, nasal sprays) suitable for nasal or ocular administration comprising steroids such as mometasone furoate have been disclosed.

On the other hand, azelastine hydrochloride has a strong bitter taste, and it is known that this bitter taste is so strong that an unpleasant taste remains even when diluted to 1 × 10 ⁶ times (US Pat. No. 5,164,194). The bitter taste of this azelastine hydrochloride is administered intranasally and then flows down the pharynx, causing unpleasant taste and irritation. US Pat. No. 6,576,677 discloses the use of polyvinylpyrrolidone and / or copolyvidone to mask the bitter taste of azelastine hydrochloride. In addition, WO2006 / 058022 discloses a pharmaceutical composition comprising azelastine hydrochloride and mometasone furoate using sucralose as a gomi masking agent.

The present invention is a pharmaceutical composition for intranasal administration comprising mometasone furoate and azelastine hydrochloride. It provides a pharmaceutical composition for intranasal administration that improves nausea by relieving bitterness and irritation.

That is, an object of the present invention is to provide a pharmaceutical composition for intranasal administration containing mometasone furoate and azelastine hydrochloride using tomate as a bitter and irritant.

According to one aspect of the present invention, in the intranasal pharmaceutical composition comprising mometasone furoate and azelastine hydrochloride, there is provided a pharmaceutical composition for intranasal administration comprising tomate as a bitter and irritant.

In the pharmaceutical composition for intranasal administration of the present invention, the amount of tomatine is 0.1? It may range from 0.5 w / v%.

In one embodiment of the invention, mometasone furoate 0.01? 1.0 w / v%; Azelastine hydrochloride 0.05? 1.0 w / v%; Thomas Martin 0.1? 0.5 w / v%; Thickener 1.0? 5.0 w / v%; Buffer 0.2? 0.6 w / v%; Surfactant 0.001? 0.1 w / v%; Isotonic agent 5.0? 10.0 w / v%; Stabilizer 0.01? 1.0 w / v%; And preservative 0.002? There is provided a pharmaceutical composition for intranasal administration comprising 0.05 w / v% in an aqueous medium. In a particularly preferred embodiment, mometasone furoate 0.05 w / v%; Azelastine hydrochloride 0.14 w / v%; Tomatin 0.25 w / v%; 2.0 w / v% of a mixture of microcrystalline cellulose and sodium carboxymethylcellulose; Citric acid 0.2 w / v%; Sodium citrate 0.28 w / v%; Polyoxyethylene sorbitan monooleate 0.01 w / v%; Glycerin 2.1 w / v%; Sorbitol 6.6 w / v%; Sodium edetate 0.1 w / v%; Benzalkonium chloride 0.02 w / v%; And remaining amount is provided a pharmaceutical composition for intranasal administration consisting of water.

Pharmaceutical compositions for intranasal administration according to the invention may be preferably administered in the form of nasal sprays.

It has been found by the present invention that tomate effectively mitigates the taste and irritation of azelastine hydrochloride, resulting in an excellent nasal feeling when administered intranasally. Thus, when tomatin is used as a bitter and irritant for the treatment of mometasone furoate and azelastine hydrochloride, administration of the nasal cavity can increase the drug compliance of the patient. In addition, formulations for intranasal administration containing mometasone furoate and azelastine hydrochloride formulated together with tomate according to the invention have excellent stability.

The present invention provides a pharmaceutical composition for intranasal administration comprising thaumatin as a bitter and irritant in the intranasal pharmaceutical composition comprising mometasone furoate and azelastine hydrochloride.

The "thaumatin" is a protein complex obtained by extracting and purifying the seeds of Thaumatococcus daniellii Benth, a West African plant, with water. It is a mixture of five tomatin proteins, of which predominantly tomatine I and II. Tomatine I and II have nearly identical amino acid sequences. Tomatine is used in food additives, and is mainly used as a sweetener and flavor improver for ice cream and soft drinks. Tomate is known as a protein produced against attack by viroid pathogens, and tomate proteins exhibit inhibitory activity against mycelial growth and sporulation by fungi.

It has been found by the present invention that tomate effectively mitigates the taste and irritation of azelastine hydrochloride, resulting in an excellent nasal feeling when administered intranasally. In the pharmaceutical composition of the present invention, the content of the tomate is 0.1 to the total composition dose. 0.5 w / v%, preferably 0.2? 0.4 w / v%, more preferably about 0.25 w / v%.

In the pharmaceutical composition for intranasal administration according to the present invention, mometasone furoate contained as a main component is 0.01? In the range of 1.0 w / v%, preferably 0.05? 0.5 w / v%, more preferably about 0.05 w / v%. In addition, azelastine hydrochloride contained as a main component is 0.05? in the range of w / v%, preferably 0.1? 0.5 w / v%, more preferably about 0.14 w / v%.

Pharmaceutical compositions for intranasal administration according to the present invention may contain additives such as thickeners, buffers, surfactants, tonicity agents, stabilizers, preservatives and the like commonly used in formulations for intranasal administration.

As the thickener, a mixture of microcrystalline cellulose and sodium carboxymethyl cellulose (for example, Avicel RC 591, Avicel RC 581, Avicel CL 611, etc.) may be used. The amount of the thickener used varies depending on the type of thickener selected, but is 1.0? 5.0 w / v%, preferably 1.0? A range of 4.0 w / v%, more preferably about 2.0 w / v% can be used.

The buffer may be a combination of an acid and a salt thereof, for example citric acid and sodium citrate. The amount of the buffer used also varies depending on the type of buffer, the buffer capacity, and the like, but is 0.2? In the range of 0.6 w / v%, preferably 0.3? It may be used in the range of 0.5 w / v%. In one embodiment, about 0.2 w / v% citric acid (or its hydrate) and 0.28 w / v% sodium citrate (or its hydrate) may be used in combination with respect to the total dose of the composition.

The surfactant performs a function of helping to suspend the poorly water-soluble drug mometasone furoate, for example, polyoxyethylene sorbitan monooleate (eg, polysorbate 40, polysorbate 60, polysorbate). Bait 80, etc.) may be used. The amount of the surfactant used also varies depending on the type of the surfactant, but is 0.001? 0.1 w / v%, preferably 0.005? It may be used in the range of 0.05 w / v%, more preferably about 0.01 w / v%.

As the isotonic agent, glycerin or sorbitol may be used, or glycerin and sorbitol may be used in combination. In the case of using saccharides such as sorbitol, it is possible to further impart sweetness properties, and thus it can be used more preferably. The amount of the isotonic agent used also varies depending on the type, but is 5.0? 10.0 w / v%, preferably 6.0? 9.0 w / v%. In one embodiment, about 2.1 w / v% glycerin and 6.6 w / v% sorbitol (eg D-sorbitol) may be used in combination with respect to the total dose of the composition.

As the stabilizer, sodium edate or its hydrate may be used, and 0.01? It may be used in the range of 1.0 w / v%, preferably about 0.1 w / v. As the preservative, conventional preservatives such as benzalkonium chloride and the like may be used. It may be used in the range of 0.05 w / v%, preferably about 0.02 w / v.

In one embodiment of the invention, mometasone furoate 0.01? 1.0 w / v%; Azelastine hydrochloride 0.05? 1.0 w / v%; Thomas Martin 0.1? 0.5 w / v%; Thickener 1.0? 5.0 w / v%; Buffer 0.2? 0.6 w / v%; Surfactant 0.001? 0.1 w / v%; Isotonic agent 5.0? 10.0 w / v%; Stabilizer 0.01? 1.0 w / v%; And preservative 0.002? There is provided a pharmaceutical composition for intranasal administration comprising 0.05 w / v% in an aqueous medium (eg, purified water, etc.).

In another embodiment of the invention, mometasone furoate 0.01? 1.0 w / v%; Azelastine hydrochloride 0.05? 1.0 w / v%; Thomas Martin 0.1? 0.5 w / v%; Mixture of microcrystalline cellulose and sodium carboxymethylcellulose 1.0? 5.0 w / v%; Mixture of citric acid and sodium citrate 0.2? 0.6 w / v%; Polyoxyethylene sorbitan monooleate 0.001? 0.1 w / v%; A mixture of glycerin and sorbitol 5.0? 10.0 w / v%; Sodium edetate 0.01? 1.0 w / v%; And benzalkonium chloride 0.002? There is provided a pharmaceutical composition for intranasal administration comprising 0.05 w / v% in an aqueous medium (eg, purified water, etc.).

In a particularly preferred embodiment of the invention, mometasone furoate 0.05 w / v%; Azelastine hydrochloride 0.14 w / v%; Tomatin 0.25 w / v%; 2.0 w / v% of a mixture of microcrystalline cellulose and sodium carboxymethylcellulose; Citric acid 0.2 w / v%; Sodium citrate 0.28 w / v%; Polyoxyethylene sorbitan monooleate 0.01 w / v%; Glycerin 2.1 w / v%; Sorbitol 6.6 w / v%; Sodium edetate 0.1 w / v%; Benzalkonium chloride 0.02 w / v%; And remaining amount is provided a pharmaceutical composition for intranasal administration consisting of water.

The pharmaceutical composition for intranasal administration according to the invention may be preferably administered in the form of a nasal spray, and thus may be preferably formulated in the form of a nasal spray.

Hereinafter, the present invention will be described in more detail with reference to examples. However, these Examples illustrate the present invention and the present invention is not limited thereto.

Examples 1 and 2. Suspensions for Nasal Spray

To prepare a nasal spray suspension in the composition and content of Table 1. The content in Table 1 represents w / v%.

Avicel RC 591 and glycerin were added to sterile purified water and dispersed in a homomixer (mixture I). Sterile purified water was added to a separate container and stirred and dissolved by adding azelastine hydrochloride, benzalkonium chloride, citrate hydrate, sodium citrate hydrate, sodium edetate hydrate, D-sorbitol and tomate (mixture II). Sterile purified water was added to a separate container and mometasone furoate and polysorbate 80 were added and dispersed (mixture III). Mixture I was mixed and stirred with mixture II, and then mixture III was mixed and stirred again. Sterile purified water was added to the resulting mixture to final volume.

ingredient Example 1 Example 2 Mometasone Furoate EP 0.05 0.05 Azelastine Hydrochloride EP 0.14 0.14 Avicel RC 591 NF 2.0 2.0 Glycerin USP 2.1 2.1 Sodium Edetate Hydrate KP 0.1 0.1 Citric Acid Carb KP 0.2 0.2 Sodium Citrate Hydrate KP 0.28 0.28 Polysorbate 80 KP 0.01 0.01 Benzalkonium Chloride KP 0.02 0.02 D-sorbitol USP 6.6 6.6 Thomas KPC 0.25 0.125 Sterilized Purified Water KP Remaining capacity (100% fit) Remaining capacity (100% fit)

Comparative Examples 1 to 3.

Instead of tomatin, using various artificial sweeteners, a suspension for nasal spray was prepared in the same manner as in Example 1 with the compositions and contents shown in Table 2 below. The content in Table 2 represents w / v%.

ingredient Comparative Example 1 Comparative Example 2 Comparative Example 3 Mometasone Furoate EP 0.05 0.05 0.05 Azelastine Hydrochloride EP 0.14 0.14 0.14 Avicel RC 591 NF 2.0 2.0 2.0 Glycerin USP 2.1 2.1 2.1 Sodium Edetate Hydrate KP 0.1 0.1 0.1 Citric Acid Carb KP 0.2 0.2 0.2 Sodium Citrate Hydrate KP 0.28 0.28 0.28 Polysorbate 80 KP 0.01 0.01 0.01 Benzalkonium Chloride KP 0.02 0.02 0.02 D-sorbitol USP 6.6 6.6 6.6 Neohesperidin 0.25 - - Sucralose NF - 0.25 - Acesulfame Potassium Supplement - - 0.25 Sterilized Purified Water KP Balance
(100% fit) Balance
(100% fit) Balance
(100% fit)

Test Example 1 Nasal Consensus Evaluation

The nasal feeling evaluation was evaluated based on the four items of "feeling bitter", "feeling sweet", "irritation" and "continuity of stimulation", the score of each item from weak to strong (or strong) 1 To 5; That is, in the case of "feeling bitter", "feeling sweet", "irritation" means that the evaluation score is 1, respectively, "bitterness is weak", "sweetness is weak", "weak irritation", the evaluation score If 5 means "strong bitterness", "sweetness is strong", "strong stimulation" means. In addition, when the evaluation score of "continuity of the stimulus" is 1 means "short stimulation is sustained", if the evaluation score is 5 means "long stimulation is sustained".

The suspensions prepared in Example 1 and Comparative Examples 1-4 were filled in a nasal spray container, sprayed 30 volunteers intranasally for 10 seconds, followed by a nasal test for the above items. The result of the nasal sensitivity test conducted as described above is shown in Table 3 below. The results in Table 3 represent the average of each evaluation score.

Bitter taste Sweetness Irritation Duration of stimulation Example 1 2.1 3.9 1.8 1.9 Comparative Example 1 4.2 2.2 3.2 1.8 Comparative Example 2 2.4 4.5 3.2 3.1 Comparative Example 3 2.9 4.2 3.4 3.6

From the results of Table 3, it can be seen that the composition of the present invention containing tomate has little bitter taste and relatively strong sweet taste, especially in terms of irritation and persistence. In the case of using the artificial sweetener neohesperidin (Comparative Example 1), the masking effect of the bitter taste was very low, and the shielding effect of the stimulus derived from azelastine hydrochloride was also very low. In addition, when sucralose was used (Comparative Example 2), the masking effect of bitterness was relatively excellent, but the shielding effect of irritation was very low. When acesulfame potassium was used (Comparative Example 3), the stimulus shielding effect was very low, and the stimulus lasted a long time. Therefore, it can be seen that the composition of the present invention containing tomate exhibits excellent nasal feeling compared with the case of using other artificial sweeteners.

Test Example 2 Mucosal Stimulation Test

An ocular mucosal stimulation test was performed that is more sensitive to irritation than the nasal mucosa and is well established and easy to interpret the results. This test was carried out in accordance with the 10-BL-455 protocol (internal control number). The preparation and testing of this protocol was carried out in the Toxicological Standards of Drugs (2009-116, KFDA, Aug. 4, 2009). The study was conducted in accordance with the Nonclinical Study Controls (2009-183, KFDA, December 22, 2009) and the OECD Principles of Good Laboratory Practice (1997). The suspension prepared in Example 1 was administered to the New Zealand White rabbit's eye mucosa at a dose of 0.1 mL / head, and symptoms were observed for 7 days.

As a result, (1) no general symptoms or deaths related to the application of the test substance were observed during the test period, (2) no weight change related to the application of the test substance was observed during the test period, and (3) application of the test substance. As a result of the observation of post eye reaction, no change was observed in both eye group and micro eye group. Both the eye and micro eye groups were evaluated as non-irritating to zero.

Therefore, the pharmaceutical composition prepared according to the present invention was found to be irritant when applied to the eye mucosa, and therefore was evaluated not to cause irritation even when applied to the nasal cavity.

Test Example 3 Physical and Chemical Stability Test

(1) long-term preservation test

The suspension prepared in Example 1 was subjected to a long term preservation test for 24 months at 20 ± 5 ° C. and 60% relative humidity. Properties were visually observed and pH was measured using a pH meter. Quantitative analysis of azelastine hydrochloride and its analogues and quantitative analysis of mometasone furoate and its analogues were all analyzed by high performance liquid chromatography (HPLC), and the respective HPLC operating conditions were as follows.

<Quantitative test conditions (HPLC) of azelastine hydrochloride and its related substances>

-Column: Capcellpak C ₁₈ Column (4.6 × 250mm, 5 μm)

-Column temperature: 30 ℃

-Detector: ultraviolet absorbance photometer (wavelength: 212nm)

Mobile phase: Add 941.1mg 1-hexanesulfone sodium to 1L of 40% acetonitrile solution

<Quantitative test conditions for mometasone furoate and its analogues (HPLC)>

-Column: Capcellpak C ₁₈ Column (4.6 × 150mm, 5 μm)

-Column temperature: 30 ℃

-Detector: ultraviolet absorbance photometer (wavelength: 254nm)

Mobile phase: Water / acetonitrile (50/50) mixture

According to the test method, the long-term storage test for 24 months at 20 ± 5 ℃ and 60% relative humidity is shown in Table 4 below.

standard Early 3 months 6 months 9 months 12 months 18 months 24 months Appearance White opaque suspension Same as left Same as left Same as left Same as left Same as left Same as left Same as left pH 4.0-6.0 4.67 4.65 4.60 4.57 4.55 4.51 4.49 Azelastine hydrochloride softness
matter Leading material A, B, C: 0.2% or less Not detected Not detected Not detected Not detected Not detected Not detected Not detected Maximum unknown: 0.2% or less 0.01% 0.01% 0.01% 0.01% 0.01% 0.02% 0.02% Total Lead: 1.0% or less 0.01% 0.01% 0.01% 0.01% 0.01% 0.02% 0.02% content 90.0-110.0% of displayed amount 99.2% 100.3% 100.1% 100.0% 99.4% 99.6% 100.0% Mometasone furoate softness
matter Maximum unknown flexible material: 0.1% or less 0.02% 0.02% 0.03% 0.03% 0.03% 0.05% 0.05% Total Lead: 0.6% or less 0.02% 0.02% 0.03% 0.03% 0.03% 0.05% 0.05% content 90.0-110.0% of displayed amount 99.7% 99.3% 99.6% 99.7% 99.5% 99.4% 99.6%

From the results of Table 4, it can be seen that the composition of the present invention has excellent physical and chemical stability for 24 months.

(2) accelerated test

The suspension prepared in Example 1 was subjected to an accelerated test for 6 months at 40 ° C. and 75% relative humidity. Formation, pH, quantitative analysis of azelastine hydrochloride and its analogue, and quantitative analysis of mometasone furoate and its analogue were carried out in the same manner as in (1) above. The results are shown in Table 5 below.

standard Early 1 month 3 months 6 months Appearance White opaque suspension Same as left Same as left Same as left Same as left pH 4.0-6.0 4.67 4.62 4.53 4.48 Azelastine hydrochloride softness
matter Leading material A, B, C: 0.2% or less Not detected Not detected Not detected Not detected Maximum unknown: 0.2% or less 0.01% 0.01% 0.02% 0.02% Total Lead: 1.0% or less 0.01% 0.01% 0.02% 0.04% content 90.0-110.0% of displayed amount 99.2% 100.3% 99.7% 99.1% Mometasone furoate softness
matter Maximum unknown flexible material: 0.1% or less 0.02% 0.03% 0.03% 0.05% Total Lead: 0.6% or less 0.02% 0.04% 0.04% 0.06% content 90.0-110.0% of displayed amount 99.7% 99.4% 99.2% 99.0%

From the results in Table 5, it can be seen that the composition of the present invention has excellent physical and chemical stability even in an accelerated test for 6 months.

Claims (6)

A pharmaceutical composition for intranasal administration comprising mometasone furoate and azelastine hydrochloride, the pharmaceutical composition for intranasal administration comprising thaumatin as a bitter and irritant. According to claim 1, wherein the content of the tomatine is 0.1? Pharmaceutical composition for intranasal administration, characterized in that 0.5 w / v%. The method of claim 1, wherein mometasone furoate 0.01? 1.0 w / v%; Azelastine hydrochloride 0.05? 1.0 w / v%; Thomas Martin 0.1? 0.5 w / v%; Thickener 1.0? 5.0 w / v%; Buffer 0.2? 0.6 w / v%; Surfactant 0.001? 0.1 w / v%; Isotonic agent 5.0? 10.0 w / v%; Stabilizer 0.01? 1.0 w / v%; And preservative 0.002? A pharmaceutical composition for intranasal administration comprising 0.05 w / v% in an aqueous medium. The method according to claim 3, wherein the mometasone furoate 0.01? 1.0 w / v%; Azelastine hydrochloride 0.05? 1.0 w / v%; Thomas Martin 0.1? 0.5 w / v%; Mixture of microcrystalline cellulose and sodium carboxymethylcellulose 1.0? 5.0 w / v%; Mixture of citric acid and sodium citrate 0.2? 0.6 w / v%); Polyoxyethylene sorbitan monooleate 0.001? 0.1 w / v%; A mixture of glycerin and sorbitol 5.0? 10.0 w / v%; Sodium edetate 0.01? 1.0 w / v%; And benzalkonium chloride 0.002? A pharmaceutical composition for intranasal administration comprising 0.05 w / v% in an aqueous medium. The method of claim 4, wherein the mometasone furoate is 0.05 w / v%; Azelastine hydrochloride 0.14 w / v%; Tomatin 0.25 w / v%; 2.0 w / v% of a mixture of microcrystalline cellulose and sodium carboxymethylcellulose; Citric acid 0.2 w / v%; Sodium citrate 0.28 w / v%; Polyoxyethylene sorbitan monooleate 0.01 w / v%; Glycerin 2.1 w / v%; Sorbitol 6.6 w / v%; Sodium edetate 0.1 w / v%; Benzalkonium chloride 0.02 w / v%; And the remaining amount is a pharmaceutical composition for intranasal administration consisting of water. The pharmaceutical composition for intranasal administration according to any one of claims 1 to 5, characterized in that it is formulated in the form of a nasal spray.